All In MedTech

Device Trial Radar · NCT01735786

EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)

EndoClotTM Absorbable Polysaccharide Hemostat for Preventing Rbleeding After Endoscopic Mucosal Resection (EMR)

Last checked: Nov 19, 2026Latest source record: Nov 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

164

Actual

Start

Apr 2010

Primary completion

Feb 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 28, 2012

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment techniques of gastrointestinal small lesions. Postoperative rebleeding is one of the common complication following EMR. Several endoscopic hemostasis methods are currently in use. EndoClot® absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic application remains unknown. This study has been designed to observe the effect of rebleeding prevention after EMR.

Conditions

  • Endoscopic Hemostasis
  • Colonic Polyps

Interventions

  • EndoClotDevice

    EndoClot hemostat is applied immediately after EMR to achieve hemostasis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rebleeding rate after EMR procedureTime frame: up to 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital of Digestive Diseases

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.